| Medicines/Item |
Section |
Status |
Link Name / Link URL |
| Abatacept |
10.01.03 |
Restricted Use
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Abatacept |
10.01.03 |
Restricted Use
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Abemaciclib |
08.01.05 |
Formulary
|
NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy |
| Abemaciclib |
08.01.05 |
Formulary
|
NICE TA563:Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Abiraterone |
08.03.04.02 |
Restricted Use
|
NICE TAG 259: Abiraterone for castration resistant prostate cancer |
| Abiraterone |
08.03.04.02 |
Restricted Use
|
NICE TA387:Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
| Adalimumab |
13.05.03 |
Restricted Use
|
NICE TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Adalimumab |
13.05.03 |
Restricted Use
|
NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa |
| Adalimumab |
01.05.03 |
Restricted Use
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
| Adalimumab |
01.05.03 |
Restricted Use
|
NICE TA187: Crohn’s disease - infliximab and adalimumab |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA199: Psoriatic arthritis |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor |
| Adalimumab |
11.04.02 |
Restricted Use
|
NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis |
| Adefovir Dipivoxil |
05.03.03.01 |
Restricted Use
|
NICE TA96: Hep B - adefovir dipivoxil and pegylated interferon alpha-2a |
| Adefovir Dipivoxil |
05.03.03.01 |
Restricted Use
|
NICE CG165: Hepatitis B (chronic) - incorporates TA96 |
| Adrenaline / epinephrine |
03.04.03 |
Formulary
|
NICE 134: Anaphylaxis: Assessment and referral after emergency treatment |
| Afatinib |
08.01.05 |
Restricted Use
|
NICE TA310: Afatinib for non-small-cell lung cancer |
| Aflibercept |
08.01.05 |
Restricted Use
|
Visual impairment due to mycopic choroidal neovascularisation: afibercept |
| Aflibercept |
08.01.05 |
Restricted Use
|
NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy |
| Aflibercept |
11.08.02 |
Restricted Use
|
NICE TA486:Aflibercept for treating choroidal neovascularisation |
| Aflibercept |
11.08.02 |
Restricted Use
|
NICE TA409:Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion |
| Alectinib |
08.01.05 |
Restricted Use
|
NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer |
| Alemtuzumab |
08.02.03 |
Restricted Use
|
NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis |
| Alirocumab |
02.12 |
Restricted Use
|
NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Alteplase |
02.10.02 |
Restricted Use
|
NICE TA264: Ischaemic stroke (acute) - alteplase |
| Amoxicillin |
05.01.01.03 |
Formulary
|
COVID19: NICE (NG165) - managing suspected or confirmed pneumonia in the community |
| Anti-D (Rh0) Immunoglobulin |
14.05.03 |
Formulary
|
NICE TAG156: Anti-D in pregnant women |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA275: Apixaban for AF |
| Apremilast |
13.05.03 |
Restricted Use
|
NICE TA 419: Apremilast for treating moderate to severe plaque psoriasis |
| Apremilast |
13.05.03 |
Restricted Use
|
NICE TA433: Apremilast for treating active psoriatic arthritis |
| Aripiprazole |
04.02.01 |
Formulary
|
Bipolar disorder (children) - aripiprazole (NICE TA292) |
| Aripiprazole |
04.02.01 |
Formulary
|
Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years (NICE TA 213) |
| Arsenic Trioxide |
08.01.05 |
Restricted Use
|
NICE TA526: treatment for acute promyelocytic leukaemia |
| Asfotase alfa |
09.08.01 |
Non Formulary
|
NICE HST6: Asfotase alfa for treating paediatric-onset hypophosphatasia |
| Ataluren |
10.02 |
Restricted Use
|
HST3 - Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene |
| Atezolizumab |
08.01.05 |
Restricted Use
|
NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy. |
| Atezolizumab |
08.01.05 |
Restricted Use
|
NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy |
| Atezolizumab |
08.01.05 |
Restricted Use
|
NICE TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer |
| Atezolizumab |
08.01.05 |
Restricted Use
|
NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable |
| Atezolizumab |
08.01.05 |
Restricted Use
|
NICE TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma |
| Atezolizumab |
08.01.05 |
Restricted Use
|
NICE TA584:Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer |
| Atezolizumab |
08.01.05 |
Restricted Use
|
NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer |
| Avatrombopag |
09.01.04 |
Restricted Use
|
NICE TA626: Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure |
| Avelumab |
08.02.03 |
Restricted Use
|
NICE TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma |
| Avelumab |
08.02.03 |
Restricted Use
|
NICE TA517: Avelumab for treating metastaic Merkel cell carcinoma |
| Axitinib |
08.01.05 |
Restricted Use
|
NICE TA333: Axitinib for advanced renal cell carcinoma |
| Axitinib |
08.01.05 |
Restricted Use
|
NICE TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma |
| Azacitidine |
08.01.03 |
Restricted Use
|
NICE TA399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts |
| Azacitidine |
08.01.03 |
Restricted Use
|
NICE TA218: azacitidine for myelodysplastic syndromes |
| Azithromycin |
05.01.05 |
Restricted Use
|
NICE evidence summary: Long-term azithromycin for CF |
| Azithromycin |
05.01.05 |
Restricted Use
|
NICE evidence summary: Long-term azithromycin for non-CF bronchiectasis |
| Baricitinib |
10.01.03 |
Restricted Use
|
NICE TA466:Baricitinib for moderate to severe rheumatoid arthritis |
| Basiliximab |
08.02.02 |
Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Basiliximab |
08.02.02 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Belimumab |
10.01 |
Restricted Use
|
NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus |
| Bendamustine |
08.01.01 |
Restricted Use
|
NICE TA 216: Bendamustine for CLL |
| Bevacizumab |
08.01.05 |
Restricted Use
|
NICE Evidence summary: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer |
| Bevacizumab |
08.01.05 |
Restricted Use
|
NICE TA263: Breast cancer with capecitabine |
| Bevacizumab |
08.01.05 |
Restricted Use
|
NICE TA214: Breast Cancer with taxane |
| Bevacizumab |
08.01.05 |
Restricted Use
|
NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab |
| Bivalirudin |
02.08.01 |
Formulary
|
NICE TAG 230 : Bivalirudin for the treatment of STEMI, 2011 |
| Bivalirudin |
02.08.01 |
Formulary
|
NICE CG 94:Unstable angina and NSTEMI |
| Blinatumomab |
08.02 |
Restricted Use
|
NICE TA450:Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia |
| Blinatumomab |
08.02 |
Restricted Use
|
NICE TA589: Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity |
| Boceprevir |
05.03.03.02 |
Non Formulary
|
NICE TA253: hepatitis |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TAG370: Bortezomib for previously untreated mantle cell lymphoma |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TAG129: Multiple myeloma - bortezomib |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TAG311: Bortezomib for induction therapy in multiple myeloma |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TAG228: 1st line treatment of multiple myeloma |
| Bosutinib |
08.01.05 |
Restricted Use
|
NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia |
| Botulinum Toxin Type A |
04.09.03 |
Restricted Use
|
NICE TA605: Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea |
| Brentuximab vedotin |
08.01.05 |
Restricted Use
|
NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma |
| Brentuximab vedotin |
08.01.05 |
Restricted Use
|
NICE TA524: for treating CD30-positive Hodgkin lymphoma |
| Brentuximab vedotin |
08.01.05 |
Restricted Use
|
NICE TA641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma |
| Brexpiprazole |
04.02.01 |
Non Formulary
|
Bipolar disorder (children) - aripiprazole (NICE TA292) |
| Brexpiprazole |
04.02.01 |
Non Formulary
|
Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years (NICE TA 213) |
| Brigatinib |
08.01.05 |
Restricted Use
|
NICE TA670: Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor |
| Brigatinib |
08.01.05 |
Restricted Use
|
NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib |
| Brolucizumab |
11.08.02 |
Restricted Use
|
NICE TA672: Brolucizumab for treating wet age-related macular degeneration |
| Budesonide |
01.05.02 |
Formulary
|
NICE: Evidence Summary (ESNM58) |
| Burosumab |
06.06.02 |
Restricted Use
|
HST8: Burosumab for treating X-linked hypophosphataemia in children and young people |
| Cabazitaxel |
08.01.05 |
Restricted Use
|
NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel |
| Cabozantinib |
08.01.05 |
Restricted Use
|
NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma |
| Cabozantinib |
08.01.05 |
Restricted Use
|
NICE TA463:Cabozantinib for previously treated advanced renal cell carcinoma |
| Cabozantinib |
08.01.05 |
Restricted Use
|
NICE TA516: Cabozantinib for treating medullary thyroid cancer |
| Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA315: Canagliflozin for type 2 diabetes |
| Cangrelor |
02.09 |
Non Formulary
|
NICE advice [ESNM64] |
| Cangrelor |
02.09 |
Non Formulary
|
NICE TA351: Reducing Artherothrombotic Events |
| Cannabidiol (CBD) |
04.08.01 |
Restricted Use
|
NICE TA615: Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome |
| Cannabidiol (CBD) |
04.08.01 |
Restricted Use
|
NICE TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA191: Gastric cancer (advanced) - capecitabine |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA61: Colorectal cancer - capecitabine and tegafur uracil |
| Caplacizumab |
08.02.03 |
Restricted Use
|
NICE TA667: Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura |
| Carbamazepine |
04.02 |
Non Formulary
|
NICE evidence summary: carbamazepine for behavioural disturbances in dementia |
| Carfilzomib |
08.01.05 |
Restricted Use
|
NICE TA657:Carfilzomib for previously treated multiple myeloma |
| Carmustine |
08.01.01 |
Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Carmustine |
08.01.01 |
Restricted Use
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Ceftolozane & tazobactam |
05.01.02 |
Restricted Use
|
NICE 2016: Evidence summary of new medicines: UTI |
| Ceftolozane & tazobactam |
05.01.02 |
Restricted Use
|
NICE 2016: Evidence summary of new medicines: intra-abdominal |
| Ceritinib |
08.01.05 |
Restricted Use
|
NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer |
| Ceritinib |
08.01.05 |
Restricted Use
|
NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer |
| Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA445:Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor |
| Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis |
| Cetirizine |
03.04.01 |
Formulary
|
NICE advice [ESUOM31]: Chronic urticaria: off-label doses of cetirizine |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA145: Head and neck cancer - cetuximab |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
| Ciclosporin |
11.99.99.99 |
Restricted Use
|
NICE TA369 - Ciclosporin for treating eye disease that has not improved despite treatment with artificial tears |
| Cinacalcet |
09.05.01.02 |
Restricted Use
|
NICE TA117: Hyperparathyroidism - cinacalcet |
| Cladribine |
08.01.03 |
Formulary
|
NICE TA616: Cladribine tablets for treating relapsing–remitting multiple sclerosis |
| Clonidine |
02.05.02 |
Formulary
|
NICE Evidence Summary: Clonidine for ADHD in children and young people |
| Clopidogrel |
02.09 |
Formulary
|
NICE Evidence summary: Clopidogrel for transient ischaemic attack |
| Cobimetinib |
08.02.04 |
Non Formulary
|
NICE TA414:Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma |
| Codeine |
04.07.02 |
Formulary
|
COVID19: NICE (NG163) Managing symptoms (incl EOL) in the community |
| Colecalciferol |
09.06.04 |
Formulary
|
NICE ES28: Vitamin D, no evidence for preventing/ treating Covid-19 |
| Colesevelam |
01.09.02 |
Formulary
|
NICE Evidence Summary: Colesevelam for bile acid malabsorption |
| Colistimethate for nebulisation |
05.01.07 |
Formulary
|
NICE ESUOM25: Non-cystic fibrosis bronchiectasis: colistimethate sodium |
| Colistimethate inhaler |
05.01.07 |
Restricted Use
|
NICE: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276) |
| Collagenase |
10.03.01 |
Non Formulary
|
NICE TA459:Collagenase clostridium histolyticum for Dupuytren’s contracture |
| Crizotinib |
08.01.05 |
Restricted Use
|
NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer |
| Crizotinib |
08.01.05 |
Restricted Use
|
NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer |
| Crizotinib |
08.01.05 |
Restricted Use
|
NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA249: Dabigatran for Stroke prevention in AF |
| Dabrafenib |
08.01.05 |
Restricted Use
|
NICE TA321:Dabrafenib for BRAF V600 +ve melanoma |
| Dabrafenib |
08.01.05 |
Restricted Use
|
NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma |
| Dabrafenib |
08.01.05 |
Restricted Use
|
NICE TA396:Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
| Daclatasvir |
05.03.03.02 |
Non Formulary
|
NICE TA364: Daclatasvir for treating chronic hepatitis C |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA597: Dapagliflozin with insulin for treating T1D |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA288: Dapagliflozin in combination therapy for treating T2D |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating T2D |
| Daratumumab |
08.01.05 |
Restricted Use
|
NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma |
| Daratumumab |
08.01.05 |
Restricted Use
|
NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma |
| Darbepoetin Alfa |
09.01.03 |
Restricted Use
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
| Darbepoetin Alfa |
09.01.03 |
Restricted Use
|
NICE NG8: Anaemia in chronic kidney disease |
| Darolutamide |
08.03.04.02 |
Restricted Use
|
NICE TA660: Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer |
| Dasabuvir |
05.03.03.02 |
Restricted Use
|
NICE TAG365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C |
| Dasatinib |
08.01.05 |
Restricted Use
|
NICE TA425:Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Dasatinib |
08.01.05 |
Restricted Use
|
NICE TA426:Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Debrisoft |
A5.07 |
Restricted Use
|
NICE MTG17: Debrisoft for acute and chronic wounds |
| Decitabine |
08.01.03 |
Non Formulary
|
NICE: Leukaemia (acute myeloid ) - decitabine (terminated appraisal) (TA270) |
| Degarelix |
08.03.04.02 |
Restricted Use
|
NICE TA404:Degarelix for treating advanced hormone-dependent prostate cancer |
| Denosumab |
06.06.02 |
Restricted Use
|
NICE: Bone metastases from solid tumours - denosumab: guidance (TA265 ) |
| Denosumab |
06.06.02 |
Restricted Use
|
NICE TA204: Osteoporotic fractures - denosumab |
| Dexamethasone |
06.03.02 |
Formulary
|
COVID 19 steroid prescribing briefing (NICE) |
| Dexamethasone intravitreal implant |
11.04.01 |
Restricted Use
|
NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis |
| Dexamethasone intravitreal implant |
11.04.01 |
Restricted Use
|
NICE TA349: Diabetic Macular Oedema |
| Diltiazem 2% Cream/Ointment |
01.07.04 |
Restricted Use
|
NICE evidence summary |
| Dimethyl fumarate |
08.02.04 |
Restricted Use
|
NICE TA320: Dimethyl fumarate for multiple sclerosis |
| Dimethyl fumarate |
08.02.04 |
Restricted Use
|
NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis |
| Dimethyl Fumarate |
13.05.02 |
Restricted Use
|
NICE TA475: Dimethyl fumarate for plaque psoriasis |
| DIMETHYL SULPHOXIDE Bladder Instillation 50% |
07.04.04 |
Restricted Use
|
NICE Unlicensed Medicine Summary 26: Dimethyl Sulfoxide Bladder Instillation |
| Dinutuximab beta |
08.02.04 |
Restricted Use
|
NICE TA538: Dinutuximab beta for treating neuroblastoma |
| Docetaxel |
08.01.05 |
Formulary
|
NICE TA101: Prostate cancer (hormone-refractory) - docetaxel |
| Docetaxel |
08.01.05 |
Formulary
|
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |
| Domperidone |
04.06 |
Formulary
|
NICE: Enteral feeds in children and young people: domperidone |
| Doxorubicin |
08.01.02 |
Formulary
|
NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma |
| Doxycycline |
05.01.03 |
Formulary
|
COVID19: NICE (NG165) - managing suspected or confirmed pneumonia in the community |
| Dronedarone |
02.03.02 |
Formulary
|
NICE TA197: Atrial fibrillation - dronedarone |
| Dulaglutide |
06.01.02.03 |
Formulary
|
NICE: Evidence Summary (ESNM59) |
| Dupilumab |
13.05.03 |
Restricted Use
|
NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis |
| Durvalumab |
08.01 |
Restricted Use
|
NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer |
| Eculizumab |
09.01.03 |
Restricted Use
|
NICE HST1: Eculizumab for atypical haemolytic uraemic syndrome |
| Eculizumab |
09.01.03 |
Restricted Use
|
NICE evidence summary: eculizumab for prevention of C3 glomerulopathy post-transplant |
| Edoxaban |
02.08.02 |
Formulary
|
NICE TA355:Edoxaban for preventing stroke/systemic embolism in non‑valvular AF |
| Eliglustat |
09.08.01 |
Non Formulary
|
NICE HST5- Eliglustat for treating type 1 Gaucher disease |
| Elosulfase alfa |
09.08.01 |
Non Formulary
|
NICE HST2: Elosulfase alfa for treating mucopolysaccharidosis type IVa |
| Eltrombopag |
09.01.04 |
Restricted Use
|
NICE TAG 293: Eltrombopag for treating chronic ITP |
| Eluxadoline |
01.04.02 |
Non Formulary
|
NICE TA471 |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating T2D |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA336: Empagliflozin for type 2 diabetes |
| Encorafenib |
08.01.05 |
Formulary
|
NICE TA668: Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer |
| Encorafenib |
08.01.05 |
Formulary
|
NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma |
| Entecavir |
05.03.03.01 |
Restricted Use
|
NICE CG165: Hepatitis B (incorporates TA153) |
| Entecavir |
05.03.03.01 |
Restricted Use
|
NICE TA153: Hepatitis B (chronic) - entecavir |
| Entrectinib |
08.01.05 |
Formulary
|
NICE TA643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer |
| Entrectinib |
08.01.05 |
Formulary
|
NICE TA644: Entrectinib for treating NTRK fusion-positive solid tumours |
| Enzalutamide |
08.03.04.02 |
Restricted Use
|
NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
| Enzalutamide |
08.03.04.02 |
Restricted Use
|
NICE TA316: Enzalutamide for prostate cancer |
| EpiFix® |
A5.04 |
Non Formulary
|
NICE EpiFix for Chronic Wounds |
| Eplerenone |
02.02.03 |
Restricted Use
|
NICE NG106: Chronic heart failure |
| Epoetin alfa |
09.01.03 |
Restricted Use
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
| Epoetin alfa |
09.01.03 |
Restricted Use
|
NICE NG8: Anaemia in chronic kidney disease |
| Epoetin beta |
09.01.03 |
Restricted Use
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
| Epoetin beta |
09.01.03 |
Restricted Use
|
NICE NG8: Anaemia in chronic kidney disease |
| Eribulin |
08.01.05 |
Restricted Use
|
NICE TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen |
| Eribulin |
08.01.05 |
Restricted Use
|
NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens |
| Erlotinib |
08.01.05 |
Restricted Use
|
NICE TA258: Lung cancer (non-small-cell) 1st line- erlotinib |
| Erlotinib |
08.01.05 |
Restricted Use
|
NICE TA227: Lung cancer (non-small-cell) maintenance - erlotinib |
| Erlotinib |
08.01.05 |
Restricted Use
|
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
| Ertugliflozin |
06.01.02.03 |
Formulary
|
NICE TA572: Ertugliflozin as monotherapy or with metformin for treating T2D |
| Ertugliflozin |
06.01.02.03 |
Formulary
|
NICE TA583: Ertugliflozin with metformin and a DPP4i for treating T2D |
| Erythromycin |
05.01.05 |
Formulary
|
NICE Evidence summary: Erythromycin for gastroparesis in adults |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA199: Psoriatic arthritis |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA195: Rheumatoid arthritis after the failure of a TNF inhibitor |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA35: Adult psoriasis |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for JIA |
| Etanercept |
13.05.03 |
Formulary
|
NICE TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Etanercept |
13.05.03 |
Formulary
|
NICE TA103: Psoriasis - efalizumab and etanercept |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA195: rheumatoid arthritis after the failure of a TNF inhibitor |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA35: Adult psoriasis |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA199: Psoriatic arthritis |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA35: Adult psoriasis |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA195: rheumatoid arthritis after the failure of a TNF inhibitor |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA199: Psoriatic arthritis |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Etelcalcetide |
09.05.01.02 |
Restricted Use
|
NICE TA448: Etelcalcetide for secondary hyperparathyroidism |
| Everolimus |
08.02.02 |
Non Formulary
|
NICE TA348: Preventing Rejection in Liver Transplant |
| Everolimus |
08.01.05 |
Restricted Use
|
NICE TA348: Preventing Rejection in Liver Transplant |
| Everolimus |
08.01.05 |
Restricted Use
|
NICE TA432:Everolimus for advanced renal cell carcinoma after previous treatment |
| Everolimus |
08.01.05 |
Restricted Use
|
NICE TA421:Everolimus with exemestane in advanced breast cancer after endocrine therapy |
| Everolimus |
08.01.05 |
Restricted Use
|
NICE TA449:Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
| Evolocumab |
02.12 |
Restricted Use
|
NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Exenatide prolonged release |
06.01.02.03 |
Formulary
|
NICE TAG 248- MR exenatide |
| Ezetimibe |
02.12 |
Formulary
|
NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia |
| Febuxostat |
10.01.04 |
Restricted Use
|
NICE TA164: Hyperuricaemia - febuxostat |
| Fentanyl |
04.07.02 |
Restricted Use
|
Moderate to severe acute post-operative pain: fentanyl transdermal patch |
| Filgrastim |
09.01.06 |
Formulary
|
NICE KTT15: Biosimilar medicines |
| Finasteride |
06.04.02 |
Restricted Use
|
NICE CG97 Lower urinary tract symptoms in men |
| Fingolimod |
08.02.04 |
Restricted Use
|
NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis |
| Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA119: Leukaemia (lymphocytic) - fludarabine |
| Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA29: Leukaemia (lymphocytic) - fludarabine |
| Fludrocortisone |
06.03.01 |
Formulary
|
Postural hypotension in adults: fludrocortisone |
| FLUNARIZINE 5mg capsules |
20 |
Formulary
|
NICE Unlicensed Evidence summary: Flunarizine for migraine prophylaxis |
| Fluocinolone intravitreal implant |
11.04.01 |
Restricted Use
|
NICE TA590: Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis |
| Fluocinolone intravitreal implant |
11.04.01 |
Restricted Use
|
NICE TA301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy |
| Fluoxetine |
04.03.03 |
Formulary
|
NICE evidence summary: Fluoxetine for hypersexuality |
| Fluticasone furoate & vilanterol |
03.02 |
Formulary
|
NICE New Medicine Evidence Summary 34: Fluticasone furoate & vilanterol inhaler |
| Fluticasone furoate, umeclidinium & vilanterol inhaler |
03.02 |
Formulary
|
COPD: fluticasone furoate, umeclidinium and vilanterol (Trelegy) |
| Follitropin Alfa biosimilar |
06.05.01 |
Restricted Use
|
NICE KTT15: Biosimilar medicines |
| Formoterol fumarate, beclometasone dipropionate and glycopyrronium bromide |
03.02 |
Formulary
|
NICE Evidence Summary (ES17) June 2018 |
| Fosfomycin |
05.01.07 |
Formulary
|
NICE Evidence summary: Fosfomycin for resistant urinary tract infections |
| Fremanezumab |
04.07.04.02 |
Formulary
|
NICE TA631: Fremanezumab for preventing migraine |
| Fulvestrant |
08.03.04.01 |
Restricted Use
|
NICE TA503: Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer |
| Fulvestrant |
08.03.04.01 |
Restricted Use
|
NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer |
| Gabapentin |
04.07.03 |
Formulary
|
CKS - Restless legs syndrome |
| Galcanezumab |
04.07.04.02 |
Restricted Use
|
NICE TA659: Galcanezumab for preventing migraine |
| Gefitinib |
08.01.05 |
Restricted Use
|
NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib |
| Gefitinib |
08.01.05 |
Restricted Use
|
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA85: Pancreatic cancer - gemcitabine |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA116: Breast cancer - gemcitabine |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Gemtuzumab ozogamicin |
08.01.05 |
Restricted Use
|
NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia |
| Gilteritinib |
08.01.05 |
Restricted Use
|
NICE TA642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia |
| Glatiramer Acetate |
08.02.04 |
Formulary
|
Glatiramer for the treatment of MS |
| Glecaprevir/Pibrentasvir |
05.03.03.02 |
Formulary
|
NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C |
| GLIADEL wafer Carmustine 7.6mg |
20 |
Formulary
|
NICE TA121: Glioma - carmustine implants and temozolomide |
| GLYCERYL TRINITRATE Ointment 0.2% |
20 |
Non Formulary
|
NICE Evidence summary: 0.2% glyceryl trinitrate ointment for chronic anal fissures |
| Glycopyrrolate/ indacaterol inhaler |
03.01.04 |
Non Formulary
|
NICE New Medicine Evidence Summary 33: indacaterol/glycopyrronium (Ultibro Breezhaler) |
| Glycopyrronium |
01.02 |
Formulary
|
NICE evidence summary: Glycopyrronium for hypersalivation |
| Glycopyrronium tablets |
20 |
Non Formulary
|
NICE Evidence Summary: glycopyrronium for hyperhidrosis |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA220: psoriatic arthritis |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Golimumab |
01.05.03 |
Restricted Use
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
| Golimumab |
10.01.03 |
Non Formulary
|
NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis |
| Guanfacine |
04.04 |
Formulary
|
NICE ESNM70: Attention deficit hyperactivity disorder in children and young people |
| Guselkumab |
13.05.03 |
Restricted Use
|
NICE TA521: Treatment in moderate to severe plaque psoriasis |
| Haloperidol |
04.02.01 |
Formulary
|
COVID19: NICE (NG163) Managing symptoms (incl EOL) in the community |
| Hydrocortisone sodium succinate |
06.03.02 |
Formulary
|
COVID 19 steroid prescribing briefing (NICE) |
| Hyoscine Butylbromide |
01.02 |
Formulary
|
COVID19: NICE (NG163) Managing symptoms (incl EOL) in the community |
| Ibrutinib |
08.01.05 |
Restricted Use
|
NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma |
| Ibrutinib |
08.01.05 |
Restricted Use
|
NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation |
| Ibrutinib |
08.01.05 |
Restricted Use
|
NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia |
| Idelalisib |
08.01.05 |
Restricted Use
|
NICE TA604: Idelalisib for treating refractory follicular lymphoma (not recommended) |
| Idelalisib |
08.01.05 |
Restricted Use
|
NICA TA359: Chronic lymphocytic leukaemia - Idelalisib |
| Imatinib |
08.01.05 |
Restricted Use
|
NICE TA425:Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Imatinib |
08.01.05 |
Restricted Use
|
NICE TA426:Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Infliximab |
01.05.03 |
Restricted Use
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
| Infliximab |
01.05.03 |
Restricted Use
|
NICE TA187: Crohns disease - infliximab & adalimumab |
| Infliximab |
01.05.03 |
Restricted Use
|
NICE TA163: Ulcerative colitis (acute manifestations) Infliximab |
| Infliximab |
13.05.03 |
Formulary
|
NICE TA134: Infliximab for psoriasis |
| Infliximab |
10.01.03 |
Restricted Use
|
NICE TA195: Rheumatoid arthritis (after failure of a TNF inhibitor) |
| Infliximab |
10.01.03 |
Restricted Use
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Infliximab |
10.01.03 |
Restricted Use
|
NICE TA199: Psoriatic arthritis |
| Infliximab |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Infliximab |
01.05.03 |
Restricted Use
|
NICE KTT15: Biosimilar medicines |
| Infliximab |
01.05.03 |
Restricted Use
|
NICE TA163: Ulcerative colitis (acute manifestations) Infliximab |
| Infliximab |
01.05.03 |
Restricted Use
|
NICE TA187: Crohns disease - infliximab & adalimumab |
| Infliximab |
01.05.03 |
Restricted Use
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
| Inotuzumab Ozogamicin |
08.01.05 |
Restricted Use
|
NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia |
| Insulin Glargine biosimilar |
06.01.01.02 |
Formulary
|
NICE KTT15: Biosimilar medicines |
| Interferon Alfa-2b |
08.02.04 |
Non Formulary
|
NICE TA75: Interferon Alfa - Chronic Hepatitis C |
| Interferon Beta-1a |
08.02.04 |
Restricted Use
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Interferon Beta-1a |
08.02.04 |
Restricted Use
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Interferon beta-1b |
08.02.04 |
Restricted Use
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Iodozyme® |
A5.03.02 |
Non Formulary
|
NICE Medtech innovation briefing on Oxyzyme and Iodozyme |
| Ipilimumab |
08.01.05 |
Restricted Use
|
NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma |
| Ipilimumab |
08.01.05 |
Restricted Use
|
NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma |
| Ipilimumab |
08.01.05 |
Restricted Use
|
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
| Isatuximab |
08.01.05 |
Restricted Use
|
NICE TA658: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma |
| Ivabradine |
02.06.03 |
Restricted Use
|
NICE Guidance on Stable Angina (2011) |
| Ivermectin |
13.10.04 |
Restricted Use
|
NICE Evidence summary: Ivermectin for difficult-to-treat scabies |
| Ivermectin cream |
13.06 |
Formulary
|
NICE new medicine summary: Inflammatory lesions of papulopustular rosacea |
| Ixazomib |
08.01.05 |
Restricted Use
|
NICE: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (TA505) |
| Ixekizumab |
13.05.02 |
Restricted Use
|
NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Ketamine oral solution |
04.07.03 |
Formulary
|
NICE Unlicensed medicine review 27: Ketamine for chronic pain |
| Lamivudine |
05.03.01 |
Restricted Use
|
CG165: Chronic Hepatitis B |
| Lanadelumab |
03.04.03 |
Restricted Use
|
NICE TA605: Lanadelumab for preventing recurrent attacks of hereditary angioedema |
| Lapatinib |
08.01.05 |
Restricted Use
|
NICE TA257: Lapatinib in HER-2 positive metastatic breast cancer |
| Larotrectinib |
08.01.05 |
Restricted Use
|
NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours |
| Ledipasvir and Sofosbuvir |
05.03.03.02 |
Restricted Use
|
NICE TAG363: Ledipasvir–sofosbuvir for treating chronic hepatitis C |
| Lefamulin |
05.01.07 |
Non Formulary
|
NICE evidence summary: Rifaximin for pouchitis |
| Lenalidomide |
08.02.04 |
Restricted Use
|
NICE TA680: Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma |
| Lenalidomide |
08.02.04 |
Restricted Use
|
NICE: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (TA505) |
| Lenvatinib |
08.01.05 |
Restricted Use
|
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma |
| Lenvatinib |
08.01.05 |
Restricted Use
|
NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine |
| Lenvatinib |
08.01.05 |
Restricted Use
|
NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma |
| Lesinurad |
10.01.04 |
Non Formulary
|
NICE: Lesinurad for treating chronic hyperuricaemia in people with gout (TA506) |
| Lesinurad & Allopurinol |
10.01.04 |
Non Formulary
|
NICE: Lesinurad for treating chronic hyperuricaemia in people with gout (TA506) |
| Levomepromazine |
04.06 |
Restricted Use
|
COVID19: NICE (NG163) Managing symptoms (incl EOL) in the community |
| Liposomal Cytarabine-Daunorubicin |
08.01.02 |
Restricted Use
|
NICE TA552: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia |
| Lorazepam |
04.01.02 |
Formulary
|
COVID19: NICE (NG163) Managing symptoms (incl EOL) in the community |
| Lorlatinib |
08.01.05 |
Restricted Use
|
NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer |
| Lubiprostone |
01.06.07 |
Non Formulary
|
NICE TA318: Lubiprostone for treating chronic idiopathic constipation |
| Lumacaftor + Ivacaftor |
03.07 |
Restricted Use
|
NICE TA398: Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation |
| Lusutrombopag |
09.01.04 |
Restricted Use
|
NICE TA617: Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure |
| Magnesium Glycerophosphate |
09.05.01.03 |
Formulary
|
NICE: Evidence Summary: Magnesium glycerophosphate |
| Mannitol inhalation |
03.07 |
Restricted Use
|
NICE: Cystic fibrosis - mannitol dry powder for inhalation (TA266) |
| Melatonin |
04.01.01 |
Non Formulary
|
NICE KTT6: Hypnotics |
| Melatonin |
04.01.01 |
Restricted Use
|
NICE Evidence summary: Melatonin for sleep disorders in children with ADHD |
| Melatonin |
04.01.01 |
Restricted Use
|
NICE guideline [NG11]:Challenging behaviour and learning disabilities |
| Mepilex Border |
A5.02.03 |
Non Formulary
|
NICE: Mepilex Border Heel & Sacrum for preventing pressure ulcers |
| Mepolizumab |
03.04.02 |
Formulary
|
NICE TA431: Mepolizumab for treating severe refractory eosinophilic asthma |
| Metformin |
06.01.02.02 |
Formulary
|
NICE Evidence summary: Metformin for PCOS in women who are not planning pregnancy |
| Midazolam |
15.01.04.01 |
Formulary
|
COVID19: NICE (NG163) Managing symptoms (incl EOL) in the community |
| Midodrine |
02.07.02 |
Formulary
|
NICE: Orthostatic hypotension: midodrine (ESNM61) |
| Midostaurin |
08.01.05 |
Restricted Use
|
NICE TA523 - untreated acute myeloid leukaemia |
| Mifamurtide |
08.02.04 |
Restricted Use
|
NICE TA235: Osteosarcoma - mifamurtide: guidance |
| Mifepristone |
07.01.02 |
Formulary
|
NICE Evidence summary: Mifepristone for induction of labour in late intrauterine fetal death |
| Migalastat |
09.08.01 |
Non Formulary
|
NICE HST4: Migalastat for treating Fabry disease |
| Minocycline |
05.01.03 |
Non Formulary
|
NICE therapeutic topic: Minocycline |
| Mirabegron |
07.04.02 |
Formulary
|
NICE: TA290 - Mirabegron for overactive bladder |
| Modafinil |
04.04 |
Restricted Use
|
NICE Evidence Summary: Modafinil for fatigue in multiple sclerosis |
| Modafinil |
04.04 |
Restricted Use
|
NICE Evidence Summary: Modafinil for excessive daytime sleepiness in Parkinson’s disease |
| Morphine |
04.07.02 |
Formulary
|
COVID19: NICE (NG163) Managing symptoms (incl EOL) in the community |
| Mycophenolate Mofetil |
08.02.01 |
Restricted Use
|
NICE Evidence summary: Mycophenolate for scleroderma |
| Mycophenolate Mofetil |
08.02.01 |
Restricted Use
|
NICE Evidence summary: Mycophenolate for SLE |
| Mycophenolic acid (sodium) |
08.02.01 |
Formulary
|
NICE Evidence summary: Mycophenolate for scleroderma |
| Naftidrofuryl |
02.06.04 |
Formulary
|
NICE TA223: Intermittent claudication drugs |
| Naftidrofuryl |
02.06.04 |
Formulary
|
NICE CG147: Lower limb peripheral arterial disease management |
| Naldemedine |
01.06.06 |
Formulary
|
NICE TA651: Naldemedine for opioid induced constipation |
| Naltrexone |
04.10.03 |
Formulary
|
NICE TA115: Drug misuse - naltrexone |
| Natalizumab |
08.02.04 |
Formulary
|
NICE TA127: Multiple sclerosis - natalizumab |
| Necitumumab |
08.01.05 |
Non Formulary
|
NICE TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer |
| Neratinib |
08.03.04.01 |
Restricted Use
|
NICE TA 612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab |
| Netupitant and Palonosetron |
04.06 |
Restricted Use
|
NICE ESNM69: Prevention of chemotherapy induced nausea and vomiting in adults |
| Nilotinib |
08.01.05 |
Restricted Use
|
NICE TA426: Dasatinib, nilotinib and imatinib for first line treatment of CML |
| Nilotinib |
08.01.05 |
Restricted Use
|
NICE TA426:Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Nilotinib |
08.01.05 |
Restricted Use
|
NICE TA425:Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Nilotinib |
08.01.05 |
Restricted Use
|
NICE TA425: Dasatinib, nilotinib and high dose imatinib for CML |
| Nintedanib |
03.11 |
Restricted Use
|
NICE TA379:Nintedanib for treating idiopathic pulmonary fibrosis |
| Nintedanib |
03.11 |
Restricted Use
|
NICE TA347: Recurrent non-small-cell lung cancer |
| Niraparib |
08.02.04 |
Restricted Use
|
NICE TA673: Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy |
| Niraparib |
08.02.04 |
Restricted Use
|
NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer |
| Nivolumab |
08.02.04 |
Restricted Use
|
NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma |
| Nivolumab |
08.02.04 |
Restricted Use
|
NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer |
| Nivolumab |
08.02.04 |
Restricted Use
|
NICE TA490:Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy |
| Nivolumab |
08.02.04 |
Restricted Use
|
NICE TA655: for advanced squamous non-small-cell lung cancer after chemotherapy |
| Nivolumab |
08.02.04 |
Restricted Use
|
NICE TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma |
| Nivolumab |
08.02.04 |
Restricted Use
|
NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma |
| Nivolumab |
08.02.04 |
Restricted Use
|
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
| Nivolumab |
08.02.04 |
Restricted Use
|
NICE TA462:Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma |
| Nivolumab |
08.02.04 |
Restricted Use
|
NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (not recommended) |
| Obeticholic acid |
01.09.01 |
Restricted Use
|
NICE TA443: Obeticholic acid for treating primary biliary cholangitis |
| Obinutuzumab |
08.02.03 |
Restricted Use
|
NICE TA343: Obinutuzumab with chlorambucil for CLL |
| Obinutuzumab |
08.02.03 |
Restricted Use
|
NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab |
| Obinutuzumab |
08.02.03 |
Restricted Use
|
NICE TA513: Obinutuzumab for untreated advanced follicular lymphoma |
| Ocrelizumab |
08.02.03 |
Restricted Use
|
NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis |
| Ocrelizumab |
08.02.03 |
Restricted Use
|
NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis |
| Ofatumumab |
08.02.03 |
Non Formulary
|
NICE TA344: Ofatumumab with chlorambucil or bendamustine for CLL |
| Olaparib |
08.02.04 |
Restricted Use
|
NICE TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer |
| Olaparib |
08.02.04 |
Restricted Use
|
NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy |
| Omalizumab |
03.04.02 |
Restricted Use
|
NICE TA278: Omalizumab for treating allergic asthma |
| Omalizumab |
03.04.02 |
Restricted Use
|
NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria |
| Ombitasvir/ paritaprevir/ ritonavir |
05.03.03.02 |
Restricted Use
|
NICE TAG365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C |
| Omega-3-Acid Ethyl Esters |
02.12 |
Non Formulary
|
NICE: schizophrenia - omega-3 fatty acid medicines |
| Omega-3-Marine Triglycerides |
02.12 |
Non Formulary
|
NICE: schizophrenia - omega-3 fatty acid medicines |
| Ondansetron |
04.06 |
Formulary
|
Ondansetron for vomiting in children with gastroenteritis- NICE evidence summary |
| Orlistat |
04.05.01 |
Formulary
|
NICE CG189: Obesity: identification, assessment and management |
| Osimertinib |
08.01.05 |
Restricted Use
|
NICE TA653: Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer |
| Osimertinib |
08.01.05 |
Restricted Use
|
NICE TA654: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer |
| Oxaliplatin |
08.01.05 |
Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
| Oxyzyme® |
A5.03.02 |
Non Formulary
|
NICE Medtech innovation briefing on Oxyzyme and Iodozyme |
| Paclitaxel |
08.01.05 |
Formulary
|
NICE TA101: Prostate cancer (hormone-refractory) - docetaxel |
| Paclitaxel |
08.01.05 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Paclitaxel - Albumin Bound Formulation |
08.01.05 |
Restricted Use
|
NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer |
| Padeliporfin dipotassium |
08.03.04.02 |
Non Formulary
|
NICE TA546: Padeliporfin not recommended for untreated localised prostate cancer |
| Palbociclib |
08.03.04.01 |
Formulary
|
NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Palbociclib |
08.03.04.01 |
Formulary
|
NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
| Panitumumab |
08.01.05 |
Restricted Use
|
NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
| Panobinostat |
08.01.05 |
Formulary
|
NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments |
| Patiromer calcium |
09.02.01.01 |
Formulary
|
NICE TA623: Patiromer for treating hyperkalaemia |
| Pazopanib |
08.01.05 |
Restricted Use
|
NICE TA 215: Pazopanib in renal cell cancer |
| Pegaptanib Sodium |
11.08.02 |
Non Formulary
|
NICE guidance on pegaptanib in AMD (August 2008) |
| Pegaspargase |
08.01 |
Formulary
|
NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia |
| Peginterferon Alfa-2a |
08.02.04 |
Non Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa & ribavirin |
| Peginterferon Alfa-2a |
08.02.04 |
Non Formulary
|
NICE TA 200: Hepatitis C - peginterferon alfa & ribavirin |
| Peginterferon Alfa-2a |
08.02.04 |
Non Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon |
| Peginterferon Alfa-2a |
08.02.04 |
Non Formulary
|
NICE TA 96: Hepatitis B - peginterferon alfa |
| Peginterferon Alfa-2a |
08.02.04 |
Non Formulary
|
NICE TA 300: Hepatitis C - peginterferon alfa |
| Pegloticase |
20 |
Non Formulary
|
NICE: TA291 - Pegloticase not recommended for severe chronic gout |
| Pegylated-liposomal doxorubicin |
08.01.02 |
Restricted Use
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Pembrolizumab |
08.01.05 |
Restricted Use
|
NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer |
| Pembrolizumab |
08.01.05 |
Restricted Use
|
NICE TA661: Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma |
| Pembrolizumab |
08.01.05 |
Restricted Use
|
NICE TA674: Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal) |
| Pembrolizumab |
08.01.05 |
Restricted Use
|
NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab |
| Pembrolizumab |
08.01.05 |
Restricted Use
|
NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy |
| Pembrolizumab |
08.01.05 |
Restricted Use
|
NICE TA357: Pembrolizumab for melanoma after ipilimumab |
| Pembrolizumab |
08.01.05 |
Restricted Use
|
NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer |
| Pembrolizumab |
08.01.05 |
Restricted Use
|
NICE TA522: Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable |
| Pemetrexed |
08.01.03 |
Restricted Use
|
NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance) |
| Pemetrexed |
08.01.03 |
Restricted Use
|
NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed |
| Pemetrexed |
08.01.03 |
Restricted Use
|
NICE TA135: Mesothelioma - pemetrexed disodium |
| Pemetrexed |
08.01.03 |
Restricted Use
|
NICE TA402:Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin |
| PENTOSAN POLYSULPHATE |
07.04.03 |
Formulary
|
Pentosan NICE TA 610 |
| Perampanel |
04.08.01 |
Formulary
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Perampanel |
04.08.01 |
Formulary
|
NICE evidence summary |
| Peristeen transanal irrigation system |
16.01 |
Non Formulary
|
NICE Peristeen transanal irrigation system |
| Pertuzumab |
08.01.05 |
Restricted Use
|
NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer |
| Pertuzumab |
08.01.05 |
Restricted Use
|
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |
| Pimecrolimus |
13.05.03 |
Formulary
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
| Pirfenidone |
03.11 |
Restricted Use
|
NICE: Idiopathic pulmonary fibrosis - pirfenidone (TA504) |
| Pixantrone |
08.01.02 |
Restricted Use
|
TA306:Pixantrone monotherapy |
| Polatuzumab Vedotin |
08.01.05 |
Restricted Use
|
NICE TA649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma |
| Pomalidomide |
08.02.04 |
Restricted Use
|
NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib |
| Ponatinib |
08.01.05 |
Restricted Use
|
NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia |
| Pramipexole |
04.09.01 |
Formulary
|
NICE CKS: Restless legs syndrome guidance |
| Prasugrel |
02.09 |
Restricted Use
|
NICE TA317 (replaces TA182): Acute coronary syndrome - prasugrel |
| Pregabalin |
04.07.03 |
Formulary
|
CKS - Restless legs syndrome |
| Promethazine hydrochloride |
03.04.01 |
Formulary
|
NICE Evidence summary: Promethazine for rapid tranquillisation in mental health settings |
| Prontosan® Wound Irrigation Solution |
A5.03.04 |
Restricted Use
|
NICE: Prontosan for Acute and Chronic wounds |
| Prucalopride |
01.06.07 |
Restricted Use
|
TA211 - Constipation (women) - prucalopride |
| Quetiapine |
04.02.01 |
Formulary
|
NICE Evidence summary: Quetiapine for generalised anxiety disorder |
| Radium-223 dichloride |
08.03.04.02 |
Restricted Use
|
NICE TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases |
| Raloxifene Hydrochloride |
06.04.01.01 |
Formulary
|
NICE quick reference guide on osteoporosis |
| Raloxifene Hydrochloride |
06.04.01.01 |
Formulary
|
NICE: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161) |
| Raloxifene Hydrochloride |
06.04.01.01 |
Formulary
|
NICE: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (TA160) |
| Ramipril |
02.05.05.01 |
Formulary
|
NICE evidence summary: ramipril for peripheral arterial disease |
| Ramucirumab |
08.01.05 |
Non Formulary
|
NICE TA403:Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer |
| Ranolazine |
02.06.03 |
Restricted Use
|
NICE Guidance on Stable Angina (2011) |
| ReCell Spray on Skin system |
A5.04 |
Non Formulary
|
NICE MTG21: ReCell Spray‑On Skin system for burn injury |
| Regorafenib |
08.01.05 |
Restricted Use
|
NICE TA488:Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours |
| Regorafenib |
08.01.05 |
Restricted Use
|
NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma |
| Remdesivir |
05.03 |
Restricted Use
|
NICE Evidence Summary 27: remdesivir for Covid-19 |
| Reslizumab |
03.04.02 |
Restricted Use
|
NICE TA479: Reslizumab for treating severe eosinophilic asthma |
| Retigabine |
04.08.01 |
Non Formulary
|
NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation |
| Ribavirin |
05.03.05 |
Restricted Use
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon |
| Ribavirin |
05.03.05 |
Restricted Use
|
NICE TA106: Hepatitis C - peginterferon alfa and ribavirin |
| Ribavirin |
05.03.05 |
Restricted Use
|
NICE TA200: Hepatitis C - peginterferon alfa and ribavirin |
| Ribociclib |
08.03.04.01 |
Restricted Use
|
NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Ribociclib |
08.03.04.01 |
Restricted Use
|
NICE TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
| Rifaximin |
05.01.07 |
Formulary
|
NICE evidence summary: Rifaximin for pouchitis |
| Riluzole |
04.09.03 |
Restricted Use
|
NICE TA20: Motor neurone disease - riluzole |
| Rituximab |
08.02.03 |
Restricted Use
|
NICE guidelines for rituximab |
| Rituximab |
10.01.03 |
Restricted Use
|
NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor |
| Rituximab |
08.02.03 |
Restricted Use
|
Rituximab for ITP-NICE evidence summary |
| Rituximab |
08.02.03 |
Restricted Use
|
NICE guidelines for rituximab |
| Rituximab |
10.01.03 |
Restricted Use
|
NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor |
| Romiplostim |
09.01.04 |
Restricted Use
|
NICE TA221: Thrombocytopenic purpura - romiplostim |
| Ropinirole |
04.09.01 |
Formulary
|
NICE CKS: Restless legs syndrome guidance |
| Rucaparib |
08.02.04 |
Restricted Use
|
NICE TA611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer |
| Ruxolitinib |
08.01.05 |
Restricted Use
|
NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis |
| Sacubitril valsartan |
02.05.05.02 |
Formulary
|
NICE TA388: Sacubitril valsartan for heart failure |
| Sarilumab |
10.01.03 |
Restricted Use
|
NICE TA485:Sarilumab for moderate to severe rheumatoid arthritis |
| Secukinumab |
13.05.03 |
Restricted Use
|
NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Secukinumab |
13.05.03 |
Restricted Use
|
NICE TA350: Plaque Psoriasis |
| Secukinumab |
13.05.03 |
Restricted Use
|
NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors |
| Sildenafil |
02.05.01 |
Formulary
|
NICE Evidence summary: Sildenafil for digital ulcers |
| Sildenafil |
02.05.01 |
Formulary
|
NICE ESUOM51: Pulmonary hypertension in neonates |
| Simeprevir |
05.03.03.02 |
Non Formulary
|
NICE TA331: Simeprevir with peginterferon alfa & ribavirin for hepatitis C |
| Siponimod |
08.02.04 |
Restricted Use
|
NICE TA656: Siponimod for treating secondary progressive multiple sclerosis |
| Sipuleucel- T |
20 |
Non Formulary
|
NICE TA322: Sipuleucel-T for prostate cancer |
| Sodium Valproate |
04.02 |
Non Formulary
|
NICE evidence summary: valproate for behavioural disturbances in dementia |
| Sodium Valproate |
04.08.01 |
Formulary
|
NICE 2019: Valproate: Summary of NICE guidance and safety advice |
| Sodium valproate |
04.02.03 |
Formulary
|
NICE 2019: Valproate: Summary of NICE guidance and safety advice |
| Sodium zirconium cyclosilicate |
09.02.01.01 |
Formulary
|
NICE TA599: Sodium zirconium cyclosilicate for treating hyperkalaemia |
| Sofosbuvir |
05.03.03.02 |
Restricted Use
|
NICE TA330: Sofosbuvir for treating chronic hepatitis C |
| Sofosbuvir and Velpatasvir |
05.03.03.02 |
Restricted Use
|
NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C |
| Sofosbuvir, Velpatasvir and Voxilaprevir |
05.03.03.02 |
Restricted Use
|
NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C |
| Somatropin |
06.05.01 |
Restricted Use
|
NICE KTT15: Biosimilar medicines |
| Somatropin |
06.05.01 |
Restricted Use
|
NICE TA188: Somatropin for growth failure in children |
| Somatropin |
06.05.01 |
Restricted Use
|
NICE TA64: Growth hormone deficiency (adults) |
| Sorafenib |
08.01.05 |
Restricted Use
|
NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma |
| Sorafenib |
08.01.05 |
Restricted Use
|
NICE TA535: Sorafenib for treating differentiated thyroid cancer after radioactive iodine. |
| Sunitinib |
08.01.05 |
Restricted Use
|
NICE TA449:Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
| Sunitinib |
08.01.05 |
Restricted Use
|
NICE TA169: Renal cell carcinoma - sunitinib |
| Sunitinib |
08.01.05 |
Restricted Use
|
NICE TA179: Gastrointestinal stromal tumours - sunitinib |
| Tacrolimus |
13.05.03 |
Formulary
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
| Tadalafil |
07.04.05 |
Formulary
|
NICE: Hyperplasia (benign prostatic) - tadalafil (terminated appraisal) (TA273) |
| Talimogene laherparepvac |
08.02.04 |
Restricted Use
|
NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma |
| Tegafur with Uracil |
08.01.03 |
Formulary
|
NICE TA61: Capcitabine and tegafur - Colorectal cancer |
| Telaprevir |
05.03.03.02 |
Non Formulary
|
NICE TA252: Telaprevir in hepatitis C |
| Temozolomide |
08.01.05 |
Formulary
|
NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) |
| Temozolomide |
08.01.05 |
Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) |
| Tenofovir Disproxil |
05.03.01 |
Restricted Use
|
NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil |
| Teriflunomide |
08.02.04 |
Restricted Use
|
NICE TA 303: Teriflunomide for relapsing remitting MS |
| Teriparatide |
06.06.01 |
Restricted Use
|
NICE: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161) |
| Teriparatide |
06.06.01 |
Restricted Use
|
NICE: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161) |
| Thiamine |
09.06.02 |
Formulary
|
NICE: Management of alcohol-related physical complications |
| Thiamine |
09.06.02 |
Formulary
|
NICE: Alcohol dependence - diagnosis, assessment and management |
| Thiamine |
09.06.02 |
Formulary
|
NICE: Alcohol dependence - diagnosis, assessment and management |
| Thiamine |
09.06.02 |
Formulary
|
NICE: Management of alcohol-related physical complications |
| Ticagrelor |
02.09 |
Restricted Use
|
NICE TAG 236: Ticagrelor for ACS |
| Ticagrelor |
02.09 |
Restricted Use
|
NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction |
| Tildrakizumab |
13.05.03 |
Restricted Use
|
NICE TA575: Tildrakizumab for treating moderate to severe plaque psoriasis |
| Tisagenlecleucel |
08.02.04 |
Formulary
|
NICE TA567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies |
| Tisagenlecleucel |
08.02.04 |
Formulary
|
NICE TA554:Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years |
| Tivozanib |
08.01 |
Restricted Use
|
NICE TA512: Tivozanib for treating advanced renal cell carcinoma |
| Tobramycin inhaler |
05.01.04 |
Restricted Use
|
NICE: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276) |
| Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA247:Tocilizumab in RA |
| Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA518: Tocilizumab for treating giant cell arteritis |
| Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Tofacitinib citrate |
10.01.03 |
Restricted Use
|
NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis |
| Tofacitinib citrate |
10.01.03 |
Restricted Use
|
NICE TA543:Tofacitinib for treating active psoriatic arthritis |
| Tofacitinib citrate |
10.01.03 |
Restricted Use
|
NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis |
| Tolvaptan |
06.05.02 |
Restricted Use
|
NICA TA358: Autosomal dominant polycystic kidney disease - tolvaptan |
| Tolvaptan |
06.05.02 |
Non Formulary
|
NICA TA358: Autosomal dominant polycystic kidney disease - tolvaptan |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA183: Cervical cancer (recurrent) - topotecan |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA184: Lung cancer (small-cell) - topotecan |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Trabectedin |
08.01.05 |
Restricted Use
|
NICE TA185: Soft tissue sarcoma - trabectedin |
| Trabectedin |
08.01.05 |
Restricted Use
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Trametinib |
08.01.05 |
Restricted Use
|
NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
| Trametinib |
08.01.05 |
Restricted Use
|
NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma |
| Tranexamic Acid |
02.11 |
Formulary
|
NICE Evidence summary: Tranexamic acid for significant haemorrhage following trauma |
| Tranexamic Acid |
02.11 |
Formulary
|
NICE guideline on heavy menstrual bleeding |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA34: Breast cancer - trastuzumab |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab |
| Trastuzumab |
08.01.05 |
Restricted Use
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
| Trastuzumab |
08.01.05 |
Restricted Use
|
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |
| Trastuzumab |
08.01.05 |
Restricted Use
|
NICE TA34: Breast cancer - trastuzumab |
| Trastuzumab |
08.01.05 |
Restricted Use
|
NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab |
| Trastuzumab |
08.01.05 |
Restricted Use
|
NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab |
| Trastuzumab |
08.01.05 |
Restricted Use
|
NICE TA34: Breast cancer - trastuzumab |
| Trastuzumab |
08.01.05 |
Restricted Use
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
| Trastuzumab |
08.01.05 |
Restricted Use
|
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |
| Trastuzumab emtansine |
08.01.05 |
Restricted Use
|
NICE TA632:Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer |
| Trastuzumab emtansine |
08.01.05 |
Restricted Use
|
NICE TA458:Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane |
| Treosulfan |
08.01.01 |
Restricted Use
|
NICE TA640: Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant |
| Ulipristal |
06.07.02 |
Non Formulary
|
NICE guidelines on heavy menstrual bleeding |
| Upadacitinib |
10.01.03 |
Restricted Use
|
NICE TA665: Upadacitinib for treating severe rheumatoid arthritis |
| UroLift system |
20 |
Non Formulary
|
NICE MTG26: UroLift for treating symptoms of BPH |
| Ustekinumab |
13.05.03 |
Formulary
|
NICE TA180: Psoriasis - ustekinumab |
| Ustekinumab |
13.05.03 |
Formulary
|
NICE TA340: Ustekinumab for treating active psoriatic arthritis |
| Ustekinumab |
13.05.03 |
Formulary
|
NICE TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Ustekinumab |
13.05.03 |
Formulary
|
NICE TA456:Ustekinumab for moderately to severely active Crohn’s disease after previous treatment |
| Ustekinumab |
13.05.03 |
Formulary
|
NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis |
| Valproate semisodium |
04.02.03 |
Formulary
|
NICE 2019: Valproate: summary of NICE guidance and safety advice |
| Varenicline |
04.10.02 |
Formulary
|
NICE TA123: Varenicline |
| Vedolizumab |
01.05.03 |
Restricted Use
|
NICE TA352: Vedolizumab for Crohn’s disease |
| Vedolizumab |
01.05.03 |
Restricted Use
|
NICE TA342: Vedolizumab for ulcerative colitis |
| Vemurafenib |
08.01.05 |
Restricted Use
|
NICE TA269: Vemurafenib for treating malignant melanoma |
| Venetoclax |
08.01.05 |
Restricted Use
|
NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia |
| Venetoclax |
08.01.05 |
Restricted Use
|
NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia |
| Venetoclax |
08.01.05 |
Restricted Use
|
NICE TA663: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia |
| Verteporfin |
11.08.02 |
Restricted Use
|
NICE Guidance 82: Age-related macular degeneration |
| Vinflunine |
08.01.04 |
Restricted Use
|
NICE: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine (TA272) |
| Vismodegib |
08.01.05 |
Restricted Use
|
NICE TA489: Vismodegib for treating basal cell carcinoma |
| Volanesorsen Sodium |
16.01 |
Non Formulary
|
HST13: Volanesorsen for treating familial chylomicronaemia syndrome |
| Vortioxetine |
04.03.03 |
Formulary
|
NICE TA 367 - Vortioxetine for treating major depressive episodes |
| Zoledronic Acid |
06.06.02 |
Formulary
|
NICE NG101: Early and locally advanced breast cancer: diagnosis and management |
| Zolpidem |
04.01.01 |
Formulary
|
NICE TAG 77: Zaleplon, zolpidem and zopiclone for the management of insomnia |
| Zopiclone |
04.01.01 |
Formulary
|
NICE TAG 77: Zaleplon, zolpidem and zopiclone for the management of insomnia |
